@article{ecc9de16d8694905a4082a9a4c8c74d6,
title = "Prolonged Central Nervous System Response in a Patient With HER2 Mutant NSCLC Treated With First-Line Poziotinib",
author = "Nishan Tchekmedyian and Bill Paxton and Francois Lebel and Lena Keossayan and Heymach, {John V.}",
note = "Funding Information: Disclosure: Dr. Tchekmedyian reports receiving personal fees from the Foundation Medicine Virtual Molecular Tumor Board and IntrinsiQ Specialty Solutions outside of the submitted work. Drs. Paxton and Lebel report receiving personal fees (employment and/or stocks) from Spectrum Pharmaceuticals, Inc. outside of the submitted work. Dr. Heymach reports receiving grants and personal fees from AstraZeneca; grants from the National Institutes of Health/National Cancer Institute, American Cancer Society, and Checkmate Pharmaceuticals; personal fees from Bristol-Myers Squibb, GlaxoSmithKline, Kairos Venture Investments, BrightPath Therapeutics, Hengrui Therapeutics, Eli Lilly, and EMD Serono; and grants and personal fees (royalties and patents) from Spectrum Pharmaceuticals, Inc. outside of the submitted work. Ms. Keossayan declares no conflict of interest.The study was funded by the Spectrum Pharmaceuticals. The patient involved in this study gave her informed consent authorizing the use and disclosure of her health information. Funding Information: The study was funded by the Spectrum Pharmaceuticals . The patient involved in this study gave her informed consent authorizing the use and disclosure of her health information.",
year = "2020",
month = nov,
doi = "10.1016/j.jtocrr.2020.100081",
language = "English (US)",
volume = "1",
journal = "JTO Clinical and Research Reports",
issn = "2666-3643",
publisher = "Elsevier Inc.",
number = "4",
}